Terlipressin Continuous Infusion Dosing for HRS-AKI
A continuous infusion rate of 0.083 mg/hour (approximately 2 mg/24 hours) provides roughly 2 mg daily, not 3.2 mg daily—to achieve 3.2 mg daily, you would need an infusion rate of approximately 0.133 mg/hour.
Dosing Strategy for Continuous Infusion
The evidence strongly supports continuous infusion over bolus dosing for terlipressin in hepatorenal syndrome-acute kidney injury (HRS-AKI), with starting doses of 2 mg/day as continuous infusion 1, 2.
Initial Dosing
- Start at 2 mg/day (0.083 mg/hour) as continuous IV infusion 1, 3
- This is lower than the FDA-approved bolus regimen (4 mg/day given as 1 mg every 6 hours) 4
- Continuous infusion achieves comparable efficacy at lower total daily doses 3
Dose Escalation Protocol
- Assess response at 24-48 hours by monitoring serum creatinine 2
- If creatinine decreases <30% from baseline, increase dose incrementally
- Maximum dose: 12 mg/day (0.5 mg/hour) 2, 3
- Typical effective doses range from 2-4 mg/day with continuous infusion 3, 5
Why Continuous Infusion is Preferred
The 2024 AGA guidelines explicitly state that continuous infusion has a lower rate of complications with similar efficacy compared to bolus dosing 1. Key advantages include:
- 35% adverse event rate with continuous infusion vs 62% with bolus (P<0.025) 3
- Lower mean daily effective dose required (2.23 mg/day vs 3.51 mg/day for bolus) 3
- Sustained hemodynamic effects with fewer cardiovascular complications 6, 7
- Comparable HRS reversal rates (76% vs 65%, not statistically different) 3
Calculating Your Specific Dose
To achieve 3.2 mg over 24 hours:
- 3.2 mg ÷ 24 hours = 0.133 mg/hour
- This represents a mid-range dose between the starting dose (2 mg/day) and higher escalation doses (4-6 mg/day)
However, starting at 3.2 mg/day is not evidence-based. The guideline-recommended approach is:
- Start at 2 mg/day (0.083 mg/hour)
- Escalate based on creatinine response at 24-48 hours
- Only increase if <30% creatinine reduction achieved
Critical Safety Considerations
Contraindications 1:
- SpO₂ <90% (absolute contraindication)
- Active coronary, peripheral, or mesenteric ischemia
- Serum creatinine >5 mg/dL (unlikely to benefit)
- ACLF Grade 3 (use with extreme caution—increased respiratory failure risk)
Monitoring requirements:
- Vital signs including pulse oximetry every 2-4 hours (not continuous monitoring required outside ICU) 1
- Watch for respiratory failure (14% incidence in CONFIRM trial) 1, 4
- Judicious albumin use to avoid volume overload 1
Albumin Co-Administration
Always give albumin concurrently 1, 2:
- Day 1: 1 g/kg (maximum 100 g)
- Subsequent days: 20-40 g/day based on volume status
- Reassess need for continued albumin after 1-2 days using clinical assessment or point-of-care ultrasound 1
Treatment Duration
- Continue until creatinine ≤1.5 mg/dL (can stop 24 hours after achieving this) 1
- Maximum 14 days 1, 4
- Discontinue if creatinine remains at or above baseline after 4 days at maximum tolerated dose 2
The evidence does not support starting at 3.2 mg/day—begin at 2 mg/day continuous infusion and titrate based on response 1, 3, 7.